Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)
NCT06235047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2024-01-31
Summary
Study on the use of a polychemotherapy scheme based on liposomal doxorubicin, vinblastine and dacarbazine (MVD) as first line in the therapy of elderly patients affected by classic Hodgkin lymphoma
Conditions
- Classic Hodgkin Lymphoma
Sponsors & Collaborators
-
Federico II University
lead OTHER
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-01
- Primary Completion
- 2023-01-01
- Completion
- 2024-01-08
Countries
- Italy
Study Locations
More Related Trials
-
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
NCT04462328 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
NCT03837873 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
NCT00907348 ·Status: UNKNOWN ·Phase: PHASE2
-
Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
NCT00120198 ·Status: TERMINATED ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05875428 ·Status: UNKNOWN ·Phase: PHASE2
-
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
NCT02420210 ·Status: TERMINATED ·Phase: PHASE2
-
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
NCT00392990 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02734771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin
NCT04069845 ·Status: UNKNOWN
-
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
NCT02406092 ·Status: COMPLETED ·Phase: PHASE3
-
DLBCL Interim Response Evaluation for Customised Therapy
NCT04226937 ·Status: UNKNOWN
-
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
NCT00923013 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
NCT04600947 ·Status: UNKNOWN ·Phase: PHASE2
-
An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
NCT02240316 ·Status: COMPLETED
-
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
NCT03161054 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122 ·Status: RECRUITING ·Phase: PHASE3
-
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
NCT00992134 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
NCT00816959 ·Status: UNKNOWN ·Phase: PHASE3
-
Radiation Free Chemotherapy for Early Hodgkin Lymphoma
NCT04866654 ·Status: RECRUITING ·Phase: PHASE2
-
CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis
NCT01325194 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
NCT02792491 ·Status: UNKNOWN ·Phase: PHASE2
-
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
NCT03298412 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00204659 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
NCT06744075 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA